DCGI approves emergency use for Zydus Cadila’s biotech drug to treat Covid-19
The Drug Controller General of India (DCGI) on Friday approved the use of the drug Viraffin during the treatment of Covid patients amid growing infection of the Covid in the country. Zydus Cadila recently sought approval from DCGI for the drug Pegylated Interferon alpha-2b (Virafin), which has been granted today. This drug has been given emergency use for use in patients with moderate symptoms of Covid.
This drug of Zydus Cadila is a single dose drug, due to which it will help to a great extent in the treatment of corona patients. During the Regulatory Filing, the company has stated that giving Virafin soon after the corona will enable the patient to recover very quickly and many types of complications will also be removed. Virafin medicines will be available for use in a hospital / institutional setup after the prescription of a medical specialist.
The company informed that after giving the drug in Phase 3 clinical trials, a significant improvement has been found in the patients who are fighting the war with Covid. During the trials, RT-PCR reports of most patients came back negative in seven days. This medicine proves to be helpful in eradicating viral rapidly.
Cadila Healthcare Limited Managing Director Dr. Shravil Patel says that the fact is that if this medicine is given to the Covid patient soon then it will prove to be capable of reducing viral load. It is known that India is currently facing the second wave of Covid. Record-breaking cases are coming up every day. In the last 24 hours, 3.32 lakh new Covid cases have been reported in the country, after which the number of active cases has crossed 24 lakh.